Actinogen receives positive scientific advice from EMA
Open PDF
| Stock | Actinogen Medical Ltd (ACW.ASX) |
|---|---|
| Release Time | 28 May 2026, 9:51 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Actinogen Receives Positive EMA Advice for Alzheimer's Disease Program
Key Points
- Actinogen received positive scientific advice from EMA
- Agreement on regulatory starting materials for Xanamem
- One additional pivotal phase 3 trial required
- EMA feedback aligns with prior FDA guidance
Full Summary
Actinogen Medical Ltd. (ASX: ACW) announced that it received successful outcomes from its scientific advice meeting with the European Medicines Agency (EMA) regarding its Alzheimer's disease program. The meeting resulted in a common understanding of the pathway to marketing approval, including the suitability of regulatory starting materials, design considerations for an additional pivotal clinical trial, and the number of ancillary trials and studies required. The EMA's feedback aligns closely with the guidance received from the FDA, providing regulatory clarity for ongoing discussions with potential development and marketing partners.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In